Hiperseksualność w chorobie Parkinsona

• Authors: Marcin Kopka

Title variants

EN

Hypersexuality in Parkinson’s disease

• Languages of publication: PL

Abstracts

PL

Hiperseksualność definiowana jest jako ciągła, wyniszczająca i uporczywa potrzeba związana z życiem seksualnym człowieka. Należy do grupy złożonych zaburzeń zachowania określanych terminem „zaburzenia kontroli impulsów”. Szacuje się, że częstość występowania hiperseksualności wśród osób z chorobą Parkinsona wynosi od 2 do 4%. U pacjentów leczonych z powodu tej choroby hiperseksualność rozpoznawana jest częściej niż w populacji ogólnej. Patofizjologia hiperseksualności u osób z chorobą Parkinsona nie została jeszcze do końca poznana. Sugeruje się, że istotną rolę odgrywa leczenie stosowane w tym schorzeniu. W większości doniesień naukowych łączono hiperseksualność z leczeniem za pomocą agonistów dopaminy, chociaż opisywano również przypadki hiperseksualności po lewodopie, inhibitorach monoaminooksydazy B czy głębokiej stymulacji mózgu. Do czynników ryzyka zwiększających ryzyko hiperseksualności u osób z chorobą Parkinsona zalicza się płeć męską, wczesny początek choroby oraz stosowanie agonistów dopaminy. Niewiele wiadomo na temat postępowania u pacjentów z chorobą Parkinsona i objawami hiperseksualności. Wyniki dwóch badań follow-up z udziałem małych grup chorych wskazują, że przerwanie leczenia agonistami dopaminy może prowadzić do całkowitego ustąpienia lub znacznej redukcji objawów hiperseksualności. Konieczne są dalsze badania, które pozwolą na opracowanie skutecznych metod terapii hiperseksualności u osób z chorobą Parkinsona.

EN

Hypersexuality is defined as a continuous, devastating and persistent need associated with human sexual life. It belongs to a group of complex behavioural disorders referred to as impulse control disorders. It is estimated that the incidence of hypersexuality in people with Parkinson’s disease ranges from 2% to 4%. In patients treated for Parkinson’s disease, hypersexuality is diagnosed more often than in the general population. The pathophysiology of hypersexuality in patients with Parkinson’s disease is not fully understood. It is suggested that the treatment of the underlying disease plays a significant role. In the literature, the majority of reports of hypersexuality cases have been linked to treatment with dopamine agonists, however, cases treated with levodopa, monoamine oxidase inhibitors or deep brain stimulation have also been reported. The risk factors of hypersexuality in patients with Parkinson’s disease include male gender, early onset of the disease and treatment with dopamine agonists. Little is known about the optimal management strategies for Parkinson’s disease patients with hypersexuality. Two long-term follow-up studies, although conducted in small groups, have indicated that discontinuation of dopamine agonists leads to full remission or clinically significant reduction of the symptoms of hypersexuality. Further studies are needed to determine how to successfully treat hypersexuality in patients with Parkinson’s disease.

Keywords

EN

choroba Parkinsona; czynniki ryzyka; hiperseksualność; leczenie

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Aktualności Neurologiczne
• Year: 2017
• Volume: 17
• Issue: 3
• Pages: 158–161

Contributors

author

Marcin Kopka

• Klinika Neurologii, Wojskowy Instytut Medycyny Lotniczej, Warszawa, Polska

References

• Avanzi M, Baratti M, Cabrini S et al.: Prevalence of pathological gambling in patients with Parkinson’s disease. Mov Disord 2006; 21: 2068–2072.
• Castrioto A, Funkiewiez A, Debû B et al.: Iowa gambling task impairment in Parkinson’s disease can be normalised by reduction of dopaminergic medication after subthalamic stimulation. J Neurol Neurosurg Psychiatry 2015; 86: 186–190.
• Ceravolo R, Frosini D, Rossi C et al.: Impulse control disorders in Parkinson’s disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord 2009; 15 Suppl 4: S111–S115.
• Cilia R, Siri C, Marotta G et al.: Functional abnormalities underlying pathological gambling in Parkinson disease. Arch Neurol 2008; 65: 1604–1611.
• Cools R, Altamirano L, D’Esposito M: Reversal learning in Parkinson’s disease depends on medication status and outcome valence. Neuropsychologia 2006; 44: 1663–1673.
• de Chazeron I, Llorca PM, Chéreau-Boudet I et al.: Hypersexuality and pathological gambling in Parkinson’s disease: a cross-sectional case-control study. Mov Disord 2011; 26: 2127–2130.
• Driver-Dunckley E, Samanta J, Stacy M: Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease. Neurology 2003; 61: 422–423.
• Gallagher DA, O’Sullivan SS, Evans AH et al.: Pathological gambling in Parkinson’s disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 2007; 22: 1757–1763.
• Gerlach M, Double K, Arzberger T et al.: Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm (Vienna) 2003; 110: 1119–1127.
• Gorzkowska A, Opala G: Zespół dysregulacji dopaminergicznej i zaburzeń kontroli impulsów. In: Sławek J, Friedman A, Bogucki A (eds.): Choroba Parkinsona i inne zaburzenia ruchowe. Vol. 1, Via Medica; Gdańsk 2011: 152–156.
• Guthrie M, Myers CE, Gluck MA: A neurocomputational model of tonic and phasic dopamine in action selection: a comparison with cognitive deficits in Parkinson’s disease. Behav Brain Res 2009; 200: 48–59.
• Harvey NS: Serial cognitive profiles in levodopa-induced hypersexuality. Br J Psychiatry 1988; 153: 833–836.
• Kaplan HI, Saddock BJ, Grebb JA: Kaplan and Sadock’s Synopsis of Psychiatry: Behavioral Sciences, Clinical Psychiatry. 7th ed., Williams and Wilkins, Baltimore, MD 1994. Krieger DM, Cardoso SV, Caumo W et al.: Parkinson’s Disease Impulsive-Compulsive Disorders Questionnaire – Current Short (QUIPCS) – translation and validation of content of Portuguese Version. J Bras Psiquiatr 2017; 66: 111–115.
• Mamikonyan E, Siderowf AD, Duda JE et al.: Long-term follow-up of impulse control disorders in Parkinson’s disease. Mov Disord 2008; 23: 75–80.
• Maréchal E, Denoiseux B, Thys E et al.: Impulse control disorders in Parkinson’s disease: an overview from neurobiology to treatment. J Neurol 2015; 262: 7–20.
• Molina JA, Sáinz-Artiga MJ, Fraile A et al.: Pathologic gambling in Parkinson’s disease: a behavioral manifestation of pharmacologic treatment? Mov Disord 2000; 15: 869–872.
• Passingham RE: The Frontal Lobes and Voluntary Action. Oxford University Press, Oxford 1993. Perachon S, Schwartz JC, Sokoloff P: Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors. Eur J Pharmacol 1999; 366: 293–300.
• Perez-Lloret S, Rey MV, Fabre N et al.: Do Parkinson’s disease patients disclose their adverse events spontaneously? Eur J Clin Pharmacol 2012a; 68: 857–865.
• Perez-Lloret S, Rey MV, Fabre N et al.: Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol 2012b; 35: 261–265.
• Phu AL, Xu Z, Brakoulias V et al.: Effect of impulse control disorders on disability and quality of life in Parkinson’s disease patients. J Clin Neurosci 2014; 21: 63–66.
• Probst CC, Winter LM, Möller B et al.: Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease (QUIP) and the QUIP-rating scale in a German speaking sample. J Neurol 2014; 261: 936–942.
• Reuter J, Raedler T, Rose M et al.: Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005; 8: 147–148.
• Rizos A, Sauerbier A, Antonini A et al.; EUROPAR and the IPMDS Non-Motor-PD-Study Group: A European multicentre survey of impulse control behaviours in Parkinson’s disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol 2016; 23: 1255–1261.
• Seppi K, Weintraub D, Coelho M et al.: The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 2011; 26 Suppl 3: S42–S80.
• Sławek J, Bogucki A, Koziorowski D et al.: Agoniści dopaminy w leczeniu choroby Parkinsona i zespołu niespokojnych nóg – rekomendacje ekspertów Polskiego Towarzystwa Choroby Parkinsona i Innych Zaburzeń Ruchowych oraz Sekcji Schorzeń Pozapiramidowych Polskiego Towarzystwa Neurologicznego. Pol Przegl Neurol 2016; 12: 1–14.
• Smeding HMM, Goudriaan AE, Foncke EMJ et al.: Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry 2007; 78: 517–519.
• Sokoloff P, Giros B, Martres MP et al.: Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347: 146–151.
• Tyne HL, Medley G, Ghadiali E et al.: Gambling in Parkinson’s disease. Mov Disord 2004; 19 (Suppl 9): S195.
• Volkow ND, Fowler JS, Wang GJ et al.: Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. Neurobiol Learn Mem 2002; 78: 610–624.
• Voon V, Fox SH: Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 2007; 64: 1089–1096.
• Voon V, Hassan K, Zurowski M et al.: Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006; 67: 1254–1257.
• Voon V, Sohr M, Lang AE et al.: Impulse control disorders in Parkinson disease: a multicenter case – control study. Ann Neurol 2011; 69: 986–996.
• Weintraub D, David AS, Evans AH et al.: Clinical spectrum of impulse control disorders in Parkinson’s disease. Mov Disord 2015; 30: 121–127.
• Weintraub D, Hoops S, Shea JA et al.: Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease. Mov Disord 2009; 24: 1461–1467.
• Weintraub D, Koester J, Potenza MN et al.: Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589–595.
• Weintraub D, Mamikonyan E, Papay K et al.: Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease–Rating Scale. Mov Disord 2012; 27: 242–247.
• Weintraub D, Siderowf AD, Potenza MN et al.: Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006; 63: 969–973.

• Document Type: article